SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?


To: Early Out who wrote (1525)4/23/1998 3:49:00 PM
From: HoodBuilder  Respond to of 9523
 
Looks like the recco worked VVUS traded to 12 7/16 up from 8



To: Early Out who wrote (1525)4/23/1998 11:34:00 PM
From: BigKNY3  Read Replies (2) | Respond to of 9523
 
JSC <<I assume Cruttenden Roth is an MM for Vivus. >>

JSC :In the case of Cruttenden Roth, the analyst on Vivus is Wole Fayemi. Prior to joining Cruttenden, Wole was an analyst at Genesis Merchant Group Securities, an underwriter for VVUS stock. As described in this March 17, 1997 issue of Fortune, Wole has been very long on VVUS for some time. In the article, he estimated MUSE sales in 1998 would reach $250 million. pathfinder.com

BigKNY3